Keihanian T, Othman M. Epidemiology, Pathogenesis, and Prognosis of Pancreatic Neuroendocrine Tumors. In: Doria C, Rogart JN, editors. Hepato-Pancreato-Biliary Malignancies [Internet]. Cham: Springer International Publishing; 2022 [cited 2025 Jun 5]. p. 623–37. Available from: https://link.springer.com/https://doi.org/10.1007/978-3-030-41683-6_36.

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors. Journal of Thoracic Oncology. 2015;10(9):1243–60.

Travis WD. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology. 2022;17(3):362–87.

WHO, editor. Thoracic tumours. 5th ed. Lyon: International agency for research on cancer; 2021. (WHO).

Quinn AM, Chaturvedi A, Nonaka D. High-grade neuroendocrine carcinoma of the lung with carcinoid morphology: A study of 12 cases. American Journal of Surgical Pathology. 2017;41(2):263–70.

Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clinical Cancer Research. 2016;

Kasajima A, Klöppel G. Neuroendocrine tumor G3 of bronchopulmonary origin and its classification. Pathology International. 2022;72(10):488–95.

Cros J, Théou-Anton N, Gounant V, Nicolle R, Reyes C, Humez S, et al. Specific genomic alterations in high grade pulmonary neuroendocrine tumours with carcinoid morphology. Neuroendocrinology. 2020;

Tang LH, Untch BR, Reidy DL, O’Reilly E, Dhall D, Jih L, et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly differentiated neuroendocrine carcinomas. Clinical Cancer Research. 2016 Feb 15;22(4):1011–7.

Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. American Journal of Surgical Pathology. 2015;39(5):683–90.

Vélayoudom-Céphise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocrine-Related Cancer. 2013;20(5):649–57.

Lacombe C, De Rycke O, Couvelard A, Turpin A, Cazes A, Hentic O, et al. Biomarkers of response to etoposide-platinum chemotherapy in patients with grade 3 neuroendocrine neoplasms. Cancers. 2021;13(4):1–14.

Derks JL, Hendriks LE, Buikhuisen WA, Groen HJM, Thunnissen E, Van Suylen RJ, et al. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2016;47:615–24.

Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. Journal of Pathology. 2017;

Elvebakken H, Perren A, Scoazec JY, Tang LH, Federspiel B, Klimstra DS, et al. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology. 2021 Aug 18;111(9):883–94.

Sorbye H, Hjortland GO, Vestermark LW, Ladekarl M, Svensson J, Sundlöv A, et al. Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. Br J Cancer [Internet]. 2025 May 17 [cited 2025 Jun 5]; Available from: https://www.nature.com/articles/s41416-025-03054-w

Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.

Derks JL, Leblay N, Lantuejoul S, Dingemans AMC, Speel EJM, Fernandez-Cuesta L. New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management. Journal of Thoracic Oncology. 2018.

Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nature Communications. 2019;10(1).

Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003 Sep 1;4(3):181–9.

Meder L, König K, Ozretic L, Schultheis AM, Ueckeroth F, Ade CP, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. International Journal of Cancer. 2016;138(4):927–38.

George J, Lim JS, Jang SJ, Cun Y, Ozretia L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;

Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clinical Cancer Research. 2014;20(4):890–903.

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature Communications. 2018;

Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe IMB, et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer. 2022;29(1):1–14.

Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, et al. Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas Are Genetically Similar and Distinct from Well-differentiated Pancreatic Neuroendocrine Tumors. Am J Surg Pathol. 2012;36(2):173–84.

Kanaan C, Bani MA, Ducreux M, Planchard D, Lamartina L, Moog S, et al. Diagnostic relevance of p53 and Rb status in neuroendocrine tumors G3 from different organs: an immunohistochemical study of 465 high-grade neuroendocrine neoplasms. Virchows Arch [Internet]. 2024 Dec 13 [cited 2025 Feb 3]; Available from: https://link.springer.com/https://doi.org/10.1007/s00428-024-04006-0

Umetsu SE, Kakar S, Basturk O, Kim GE, Chatterjee D, Wen KW, et al. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap. Modern Pathology. 2023 Mar;36(3):100065.

Tanaka M, Shinozaki-Ushiku A, Kunita A, Yasunaga Y, Akamatsu N, Hasegawa K, et al. High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma. Pathology International. 2022 Aug 1;72(8):411–8.

Kasajima A, Pfarr N, Mayr EM, Ura A, Moser E, Von Werder A, et al. Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation. Endocr Pathol. 2024 Dec;35(4):313–24.

Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G, et al. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. Eur J Cancer. 2021 Jul;152:100–15.

Dehainault C, Michaux D, Pagès-Berhouet S, Caux-Moncoutier V, Doz F, Desjardins L, et al. A deep intronic mutation in the RB1 gene leads to intronic sequence exonisation. Eur J Hum Genet. 2007 Apr;15(4):473–7.

Schieffer KM, Feldman AZ, Kautto EA, McGrath S, Miller AR, Hernandez-Gonzalez ME, et al. Molecular classification of a complex structural rearrangement of the RB1 locus in an infant with sporadic, isolated, intracranial, sellar region retinoblastoma. Acta Neuropathol Commun. 2021 Apr 7;9(1):61.

Febres-Aldana CA, Chang JC, Ptashkin R, Wang Y, Gedvilaite E, Baine MK, et al. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Clinical Cancer Research. 2022;28(21):4702–13.

Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 2002 21:45. 2002 Oct 4;21(45):6908–14.

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology 2022 33:1. 2022 Mar 16;33(1):115–54.

Piqueret-Stephan L, Marcaillou C, Reyes C, Honoré A, Letexier M, Gentien D, et al. Massively parallel DNA sequencing from routinely processed cytological smears. Cancer Cytopathology. 2016 Apr 1;124(4):241–53.

Kenny, D.A, Kashy, D.A., &Cppk WL. No Title. Dyadic data analysis. 2006.

Leblanc V, May P. Activation and post-translational modifications of p53 following DNA damage. Medecine/Science. 2002;53:577–84.

Hijioka S, Hosoda W, Matsuo K, Ueno M, Furukawa M, Yoshitomi H, et al. Cancer Therapy: Clinical Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. Clin Cancer Res. 2019;23(16).

Derks JL, Leblay N, Thunnissen E, Van Suylen RJ, Den Bakker M, Groen HJM, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clinical Cancer Research. 2018;24(1):33–42.

Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, et al. Reciprocal Rb Inactivation and p16INK4 Expression in Primary Lung Cancers and Cell Lines. Cancer Research. 1995;55(3):505–9.

Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, et al. Expression of p16 and lack of pRB in primary small cell lung cancer. The Journal of Pathology. 1999 Nov 1;189(3):358–62.

Geradts J, Fong KM, Zimmerman P V., Maynard R, Minna JD. Correlation of abnormal RB, p16(ink4a), and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clinical Cancer Research. 1999;5(4):791–800.

Konukiewitz B, Jesinghaus M, Steiger K, Schlitter AM, Kasajima A, Sipos B, et al. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum Pathol. 2018 Jul;77:70–9.

Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, et al. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. Modern Pathology. 2019;32(2):290–305.

Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016 Jul 13;2(4):247-258.

Pakkanen P, Silvoniemi A, Aro K, Bäck L, Irjala H, Aaltonen LM, Hagström J, Haglund C, Laine J, Minn H, Huvila J. Simultaneous p53 and p16 Immunostaining for Molecular Subclassification of Head and Neck Squamous Cell Carcinomas. Head Neck Pathol. 2024 Aug 7;18(1):73.